The Plant-Based Biologics Market is estimated to be valued at Us$ 21.45 Mn in 2023 and is expected to exhibit a CAGR Of 3.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:

Plant-based biologics refer to the production of therapeutic proteins in plants for applications in biomedicine and pharmacotherapy. They provide an economically and environmentally sustainable alternative to traditional manufacturing in cell cultures and microbial fermentation. Key therapeutic proteins produced in plants include antibodies, hormones, interleukins and vaccines. The production efficiency and scalability of plant systems allow for large-scale and cost-effective manufacturing to address the biologics supply shortage.

Market Dynamics:

The growth of the plant-based biologics market is supported by increasing demand for sustainable production methods for biologics. Traditional production routes utilize fermentation by mammalian or microbial cells which have a large carbon footprint. Plants provide a renewable biomass that can be cultivated at scale while reducing resource consumption through photosynthesis. Furthermore, plants offer significant advantages over other systems for establishing complex post-translational modifications akin to those found in humans. This allows for improved efficacy and safety of biologics produced. Additionally, plants provide a safe, low-cost platform for manufacturing vaccines and antibodies against emerging pathogens which is driving investments in this area. The presence of well-established agriculture sector for producing recombinant proteins in major crops such as tobacco, maize and soy further supports market growth.

SWOT Analysis

Strength: The plant-based biologics market offers various advantages over traditional production systems. It provides strong intellectual property protection, scalability of production, and rapid genetic engineering to create novel products. Plant production platforms are also less expensive and have higher production yields compared to microbial and mammalian systems.

Weakness: Regulatory hurdles and acceptance issues exist as plant-based systems are relatively new. There are challenges in achieving the required human-like post-translational modifications and glycoprotein folding associated with some human therapeutic proteins. Purification of target proteins from plants can also be complex.

Opportunity: Growing demand for cost-effective biologics and vaccines drives the need for scalable production platforms. Plants provide an appealing alternative to manufacture existing as well as emerging biologics and meet the global shortage. The flexible molecular farming technique in plants allows rapid production of several recombinant proteins.

Threats: Dependence on transgenic technologies raises public and regulatory concerns. Safety testing for toxins and allergens is essential but increases costs and development timelines. Intellectual property issues in certain nations can impede commercialization. Competition exists from conventional microbial, animal, and human cell culture systems.

Key Takeaways

The Global Plant-Based Biologics Market Demand is expected to witness high growth, exhibiting CAGR of 3.4% over the forecast period, due to increasing demand for affordable biologics and vaccines.

Regional analysis:

North America dominates the global plant-based biologics market currently owing to strong government support and availability of advanced technologies. However, Asia Pacific is envisioned to emerge as the fastest growing market due to rising R&D spending, lower manufacturing costs, and presence of key players in nations like China and India.

Key players operating in the plant-based biologics market are Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., Eleva GmbH, Kentucky Bioprocessing, LLC, Solarvest Bioenergy Inc., and Byondis B.V.

Read More : http://insightsmarket.weebly.com/blog/the-plant-based-biologics-market-is-estimated-to-witness-high-growth-owing-to-increasing-demand-for-sustainable-therapeutics